The stock of Moleculin Biotech Inc (NASDAQ: MBRX) has decreased by -11.52 when compared to last closing price of 1.39.Despite this, the company has seen a loss of -25.90% in its stock price over the last five trading days. prnewswire.com reported 2025-01-27 that – Walter Klemp, CEO of Moleculin, provides an update on the Company’s Phase 3 pivotal trial of Annamycin for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML) (the “MIRACLE” trial) – Watch the “What This Means” segment here HOUSTON, Jan. 27, 2025 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin participated in a Virtual Investor “What This Means” segment. As part of the segment, Mr.
Is It Worth Investing in Moleculin Biotech Inc (NASDAQ: MBRX) Right Now?
Company’s 36-month beta value is 1.93.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBRX is 3.27M, and currently, short sellers hold a 5.19% ratio of that floaft. The average trading volume of MBRX on February 05, 2025 was 56.62K shares.
MBRX’s Market Performance
MBRX stock saw a decrease of -25.90% in the past week, with a monthly decline of -30.51% and a quarterly a decrease of -52.69%. The volatility ratio for the week is 12.17%, and the volatility levels for the last 30 days are 10.86% for Moleculin Biotech Inc (MBRX). The simple moving average for the past 20 days is -26.62% for MBRX’s stock, with a -59.20% simple moving average for the past 200 days.
Analysts’ Opinion of MBRX
Many brokerage firms have already submitted their reports for MBRX stocks, with Oppenheimer repeating the rating for MBRX by listing it as a “Outperform.” The predicted price for MBRX in the upcoming period, according to Oppenheimer is $14 based on the research report published on July 18, 2022 of the previous year 2022.
MBRX Trading at -39.20% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.12% of loss for the given period.
Volatility was left at 10.86%, however, over the last 30 days, the volatility rate increased by 12.17%, as shares sank -31.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.96% lower at present.
During the last 5 trading sessions, MBRX fell by -25.90%, which changed the moving average for the period of 200-days by -71.26% in comparison to the 20-day moving average, which settled at $1.6762. In addition, Moleculin Biotech Inc saw -27.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBRX
Current profitability levels for the company are sitting at:
- -71.22 for the present operating margin
- 0.76 for the gross margin
The net margin for Moleculin Biotech Inc stands at -74.26. The total capital return value is set at -1.62. Equity return is now at value -141.49, with -95.84 for asset returns.
Based on Moleculin Biotech Inc (MBRX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -47.8. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -65.87.
Currently, EBITDA for the company is -29.5 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of -11.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In a nutshell, Moleculin Biotech Inc (MBRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
